ABSTRACT
The impact of FVL, prothrombin mutation (PTM), and methylenetetrahydrofolate reductase (MTHFR) polymorphism on thrombosis risk was determined in another study, which included a cohort of 175 patients with gastrointestinal adenocarcinoma.20 An increased prevalence of PTM was found in patients compared with the normal population (5.7% vs 0.8%, p = 0.028). One hundred and forty-seven patients did not have VTE (group A), whereas 28 of patients had VTE during the period following tumor diagnosis (group B). Only 6.8% of group A patients, but 21.4% of the patients in group B, had thrombosis before the diagnosis of cancer (OR = 3.7, p = 0.025). Heterozygosity for the FVL mutation was present in 4.8% of the patients in group A and in 17.9% of group B (OR = 4.4, p = 0.026). This study demonstrated a significant effect of FVL on thrombosis in patients with malignancy and also suggested that PTM may be a risk factor in cancer thrombosis.
